Navigation Links
uBiome Receives Patent for Microbiome-Derived Diagnostics and Therapeutics for Immune-Microbial Dysfunction
Date:12/14/2018

uBiome, the leader in microbial genomics, announced the issue of patent number 9,703,929 entitled “Method and System for Microbiome-Derived Diagnostics and Therapeutics” by the US Patent and Trademark Office on July 11, 2017 with a priority date of October 21, 2014. The patent is an invention by uBiome collaborators Dr. Zachary Apte, Dr. Daniel Almonacid, Dr. Jessica Richman, and Dr. Siavosh Rezvan Behbahani, and expands upon previously filed intellectual property.

The patented technology involves characterizing an immune-microbial dysfunction and generating a therapy model by analyzing biological samples from uBiome’s proprietary database. The microbiome compositions obtained with these products are useful in assisting a health care provider with the diagnosis of immune-microbial dysfunctions such as irritable bowel syndrome (IBS), Crohn’s disease, ulcerative colitis, and celiac disease, among others.

This issuance creates the possibility of designing a therapy based on the modification of the microbiota using prebiotics and probiotics. It also opens up the possibility of predicting the likelihood of occurrence of immune-microbial dysfunction in individuals.

“uBiome’s goal is to advance the science of the microbiome, and this technology allows us to do just that,” Jessica Richman, PhD, co-founder and CEO of uBiome, said. “Diagnostics and therapeutics are an exciting frontier for microbiome-derived analysis and we are pleased to have been granted this patent.”

For more information about our science and patents, visit http://www.ubiome.com/science/#patents.
_____
About uBiome
Founded in 2012, uBiome is the leader in microbial genomics. The Company’s mission is to advance the science of the microbiome and make it useful to people. uBiome combines its patented proprietary precision sequencing™ with machine learning and artificial intelligence to develop wellness products, clinical tests, and therapeutic targets. uBiome has filed for over 250 patents on its technology, which includes sample preparation, computational analysis, molecular techniques, as well as diagnostic and therapeutic applications.

uBiome’s commercial products include SmartGut™, the world’s first sequencing-based clinical microbiome test, which identifies microbes in the gut for patients with chronic gut conditions such as IBD, IBS, Crohn’s Disease, and ulcerative colitis; SmartJane™, the first sequencing-based women’s health screening test, which genotypes all 19 clinically relevant strains of HPV, identifies four common STDs, and surveys more than 20 vaginal microbes associated with bacterial vaginosis and other conditions; and Explorer™, a health and wellness product to understand the role that food and lifestyle can play in wellness.

uBiome’s platform has been used by hundreds of thousands of consumers, patients, and doctors and more than 200 research institutions around the world, including the US Centers for Disease Control (CDC), US National Institutes of Health (NIH), Harvard University, Stanford University, the Massachusetts Institute of Technology (MIT), University of California, San Francisco, Oxford University, and the University of Sydney.

Since its launch, the company has received widespread recognition including CNN 10: Startups to Watch, the IVY Technology Award, CNN Future 30, and was named one of Fast Company’s Most Innovative Companies in Healthcare in 2016 and in Data Science in 2018, as well as a Technology Pioneer from the World Economic Forum in 2018. For more information, visit http://www.uBiome.com.

Read the full story at https://www.prweb.com/releases/ubiome_receives_patent_for_microbiome_derived_diagnostics_and_therapeutics_for_immune_microbial_dysfunction/prweb15986048.htm.


'/>"/>
Source: PRWeb
Copyright©2018 Vocus, Inc.
All rights reserved


Related biology news :

1. uBiome Appoints Dr. Amir Zarrinpar, MD, PhD, Assistant Professor in the Division of Gastroenterology at UC San Diego, to its Medical Advisory Board
2. uBiome Appoints Dr. Brandon Wuerth, MD, Founder of IBDwatch, to its Medical Advisory Board
3. uBiome Appoints Dr. Emeran Mayer, MD, World-Renowned Gastroenterologist and Neuroscientist, to its Medical Advisory Board
4. uBiome Appoints Dr. Jill Carnahan, MD, Functional Medicine Expert, to its Medical Advisory Board
5. uBiome Appoints Dr. Catherine Lozupone, PhD, Respected Microbiologist, to its Scientific Advisory Board
6. uBiome Appoints Leading Biochemist Dr. Joseph DeRisi to Board of Directors
7. uBiome Appoints Dr. Donnica Moore, MD, Women's Health Expert and Advocate, to its Medical Advisory Board
8. uBiome Appoints Dr. Jonathan Braun, MD, PhD, Prominent UCLA Physician-Researcher, to its Scientific Advisory Board
9. uBiome Appoints Kathie Swift, MS, RDN, FAND, Co-founder of the Integrative and Functional Nutrition Academy, to its Scientific Advisory Board
10. uBiome Appoints Dr. Steven Medwell, MD, Distinguished Colorectal Surgeon, to its Medical Advisory Board
11. NDA Partners Expert Consultant Vinod Shah, PhD, Receives AAPS Award for Global Leadership
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/14/2019)... CITY, and MARTINSRIED, Germany (PRWEB) , ... August ... ... high-throughput antibody screening and characterization, announced today that they have opened a Customer ... platform has fueled the need for the new office. , The Munich CEC ...
(Date:8/14/2019)... , ... August 13, 2019 , ... ... Team, Division of Molecular Pathology, Institute of Cancer Research (ICR) in a ... to learn about the process of biomarker and companion diagnostic development including machine ...
(Date:8/6/2019)... ... August 06, 2019 , ... ... manufacturing with clinical, regulatory and GMP manufacturing experience. In November it spun ... With extensive regulatory experience and one of the first cGMP cell ...
Breaking Biology News(10 mins):
(Date:6/26/2019)... ... ... Alice Branton today released research results from preclinical trials on the beneficial ... prove to be beneficial for treating Hypomagnesemia. , The preclinical trial shows:, ... , Over 142% increase in particle size , Over 3% ...
(Date:6/18/2019)... ... 18, 2019 , ... Personalized Stem Cells, Inc (“PSC”), a human ... FDA for use of a person’s own adipose-derived stem cells to treat their osteoarthritis. ... knee. This IND is the first of several planned clinical trials which will ...
(Date:6/11/2019)... ... June 10, 2019 , ... ... distribution network with the appointment of Biofeedback Tech Ltd as its ... are an essential part of many therapeutic treatments and clinical assessment protocols to ...
(Date:6/11/2019)... , ... June 10, 2019 , ... ... IOPP will add 80 of its scientific journals to DeepDyve’s rental service for ... to DeepDyve’s continually expanding library of more than 20 million articles, sourced from ...
Breaking Biology Technology: